

Olanzapine

Form	Powder for solution for injection	Store below 25°C in original packaging.														
Reconstitution	Withdraw 2.1 ml of water for injection into a sterile syringe. Inject into the vial. Rotate the vial until the contents have completely dissolved, giving a yellow coloured solution. The vial contains a deliberate overage. 1mg olanzapine is retained in the vial and should be discarded.															
Compatibility & Stability	WFI															
Administration	IM Injection															
	<table><tr><th>Dose (mg)</th><th>Volume of Injection(mL)</th></tr><tr><td>10</td><td>2.0</td></tr><tr><td>7.5</td><td>1.5</td></tr><tr><td>5</td><td>1.0</td></tr><tr><td>2.5</td><td>0.5</td></tr></table>		Dose (mg)	Volume of Injection(mL)	10	2.0	7.5	1.5	5	1.0	2.5	0.5				
	Dose (mg)	Volume of Injection(mL)														
	10	2.0														
7.5	1.5															
5	1.0															
2.5	0.5															
	CSCI – unlicensed															
	<table><tr><th>Dose (mg)</th><th>Volume (mL)</th></tr><tr><td>20</td><td>4.0</td></tr><tr><td>15</td><td>3.0</td></tr><tr><td>10</td><td>2.0</td></tr><tr><td>7.5</td><td>1.5</td></tr><tr><td>5</td><td>1</td></tr><tr><td>2.5</td><td>0.5</td></tr></table> - Withdraw the required dose into a 20ml syringe. - Dilute this solution to a final volume of 18ml with WATER FOR INJECTION. - Draw a small amount of air into the syringe, cap and mix well. Expel the air once mixed and confirm final volume is 18ml. - Due to incompatibility of Olanzapine with other drugs, it must be infused via a separate syringe driver		Dose (mg)	Volume (mL)	20	4.0	15	3.0	10	2.0	7.5	1.5	5	1	2.5	0.5
Dose (mg)	Volume (mL)															
20	4.0															
15	3.0															
10	2.0															
7.5	1.5															
5	1															
2.5	0.5															
Monitoring	Blood pressure, pulse and respiratory rate should be monitored for at least 4 hours after intramuscular injection, particularly in those also receiving a benzodiazepine or another antipsychotic (leave at least one hour between administration of olanzapine intramuscular injection and parenteral benzodiazepines).															
Additional Information	- When prescribing, dispensing, or administering, check that this injection is the correct preparation—this preparation is usually used in hospital for the rapid control of an <i>acute episode</i> and should not be confused with depot preparations that are usually used in the community or clinics for <i>maintenance</i> treatment. - Do not give to patients with known risk of narrow-angle glaucoma.															

This information has been summarised to act as a guide for those administering IV medication. The monograph should be used in conjunction with the drug data sheet and BNF for information on dose, adverse effects, cautions and contra-indications. Further information is available from Pharmacy on 22146 or 22542

- | | |
|--|---|
| | <ul style="list-style-type: none">• Do not give in cardiac illness: acute myocardial infarction, unstable angina, severe hypotension or bradycardia, sick sinus syndrome, recent heart surgery.• Olanzapine is not recommended for use in patients with dementia-related psychosis and/or behavioural disturbances because of an increase in mortality and the risk of cerebrovascular accident.• The use of olanzapine in the treatment of dopamine agonist associated psychosis in patients with Parkinson's disease is not recommended. |
|--|---|

Information provided relates to Zyprexa® (Cheplapharm) last updated 28/4/26